White Paper: Drug Repositioning Driving R&D Productivity

This is a paid advertisement for SmartBrief readers.

The content does not necessarily reflect the view of SmartBrief or its Association partners.

If you are having trouble viewing this message in your e-mail client, please see the web version here

Our latest white paper, Knowledge-Based Drug Repositioning to drive R&D Productivity, is now available. In this report, Thomson Reuters analysts assess current trends in drug repositioning, and outline best practices for successful strategies. Download the whitepaper to find out more about these strategies Analysis of Thomson Reuters benchmarking data suggest repositioned assets have greater success rates relative to NMEs while reducing cycle times and decreasing development costs.  (CMR data -Repositioned drugs are defined as NCEs seeking new indications once the lead indication has successfully transitioned into Phase III. It excludes new formulations, doses, routes of administration for an existing indication) NEW HOME. NEW HOPE. Drug Repositioning Solutions from Thomson Reuters The business case for drug repositioning is strong: you maximize return on R&D, market your drug faster, and generate new income. Finding a new home for an existing drug that might have more potential or a compound that didn't succeed the first time out offers a lot of people new hope, while helping to grow your business. Our experts help you evaluate repurposing opportunities by connecting data on drugs, disease pathways, and proteins in three ways: • DRUG FOCUS - A structure similarity based method to find new indications that help exploit the full value of a drug. • TARGET FOCUS - Pathway analysis and protein structure methods help find new therapeutic uses for the library of drugs that modulate a particular mechanistic target or pathway • DISEASE FOCUS - Find new approaches to drug intervention in a disease or sub-population and identify available candidate To learn more about Drug Repositioning at Thomson Reuters, or about their Life Sciences Professional Services group, visit http://ip-science.thomsonreuters.com/info/drugrepositioning    FINDING YOUR COMPOUND A NEW HOME OFFERS A LOT OF PEOPLE NEW HOPE. WE CAN HELP.

About this email: BIO SmartBrief will occasionally send emails from our advertising partners promoting products and services determined to be of interest and relevance to our readers. Each email is carefully considered on a case-by-case basis. If you do not want to receive these emails, you can unsubscribe from them by clicking here. SmartBrief, Inc.® 555 11th ST NW, Suite 600, Washington, DC 20004